U2TH34.SA United Therapeutics Corporation

Healthcare Drug Manufacturers - Specialty & Generic Sao Paulo Exchange
164.64 BRL
Close of Nov 5, 2026
119.64 164.64
Market cap
BRL 141B
P/E
22.3x
P/B
4.06x
ROE
19.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is U2TH34.SA undervalued?

Graham number
Price164.64
Graham value82.15
Premium100.4%

U2TH34.SA trades 100.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

United Therapeutics Corporation fundamental analysis

No fundamental analysis for United Therapeutics Corporation yet.

United Therapeutics Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish sy…

Full company profile